Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist.
The DOI matches its Crossref record.
Abstract
The authors describe here the pharmacological properties of bosentan, a new nonpeptide mixed antagonist of endothelin (ET) receptors, obtained by structural optimization of the less potent Ro 46-2005 [Ro 46-2005 (4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(3-methoxy-phenoxy)-4-pyrimidinyl ]-benzenesulfonamide]. Bosentan (Ro 47-0203, 4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2,2'-bipyr imidin-4-yl]-benzenesulfonamide) competitively antagonized the specific binding of [125I]-labeled ET-1 on human smooth muscle cells (ETA receptors) with a Ki of 4.7 nM and on human placenta (ETB receptors) with a Ki of 95 nM. It also inhibited the binding of selective ETB ligands on porcine trachea. Contractions induced by ET-1 in isolated rat aorta (ETA) and by the selective ETB agonist sarafotoxin S6C in rat trachea were competitively inhibited by bosentan (pA2 = 7.2 and 6.0, respectively), as was the endothelium-dependent relaxation to sarafotoxin S6C in rabbit superior mesenteric artery (pA2 = 6.7). The binding of 40 other peptides, prostaglandins, ions and neurotransmitters was not significantly affected by bosentan, which shows its specificity for ET receptors. In vivo, bosentan inhibited the pressor response to big ET-1 both after i.v. and oral administration, with a long duration of action and no intrinsic agonist activity. It also inhibited the depressor and pressor effect of ET-1 and sarafotoxin S6C. Thus, bosentan is the most potent orally active antagonist of ET receptors described so far. Its pharmacological profile makes bosentan a potentially useful drug in the management of clinical disorders associated with vasoconstriction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Andrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
Drugs, their targets and the nature and number of drug targets
Imming, P., Sinning, C., & Meyer, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2132 · Cited by 839
Davenport, A. P., Hyndman, K. A., Dhaun, N., Southan, C., Kohan, D. E., Pollock, J. S., Pollock, D. M., Webb, D. J., & Maguire, J. J. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011833 · Cited by 772
General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition
Mager, D. E., & Jusko, W. J. (2001) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1023/a:1014414520282 · Cited by 605
Krum, H., Viskoper, R. J., Lacourciere, Y., Budde, M., & Charlon, V. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803193381202 · Cited by 570
The determination and interpretation of the therapeutic index in drug development
Muller, P. Y., & Milton, M. N. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3801 · Cited by 563
The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 556
PATHOPHYSIOLOGY OF ENDOTHELIN IN THE CARDIOVASCULAR SYSTEM
Miyauchi, T., & Masaki, T. (1999) · Annual Review of Physiology · doi:10.1146/annurev.physiol.61.1.391 · Cited by 544
Mulder, P., Richard, V., Derumeaux, G., Hogie, M., Henry, J. P., Lallemand, F., Compagnon, P., Macé, B., Comoy, E., Letac, B., et al. (1997) · Circulation · doi:10.1161/01.cir.96.6.1976 · Cited by 360
Endothelins in the normal and diseased kidney
Kohan, D. E. (1997) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(97)90004-4 · Cited by 354
Barst, R. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00005-5 · Cited by 350
Treiber, A., Schneiter, R., Häusler, S., & Stieger, B. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.013615 · Cited by 299
“Bosentan (Tracleer) is a dual endothelin receptor antagonist (Clozel et al., 1994; Neidhart et al., 1996) approved as the first oral treatment for pulmonary arterial hypertension (PAH) (Rubin et al., 2002).”
BackgroundSütsch, G., Kiowski, W., Yan, X.-W., Hunziker, P., Christen, S., Strobel, W., Kim, J.-H., Rickenbacher, P., & Bertel, O. (1998) · Circulation · doi:10.1161/01.cir.98.21.2262 · Cited by 287
Li, J. S., Larivière, R., & Schiffrin, E. L. (1994) · Hypertension · doi:10.1161/01.hyp.24.2.183 · Cited by 286
Sakai, S., Miyauchi, T., Sakurai, T., Kasuya, Y., Ihara, M., Yamaguchi, I., Goto, K., & Sugishita, Y. (1996) · Circulation · doi:10.1161/01.cir.93.6.1214 · Cited by 286
Clinical Pharmacology of Bosentan, a Dual Endothelin Receptor Antagonist
Dingemanse, J., & van Giersbergen, P. L. M. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443150-00003 · Cited by 272
Role of the endothelin axis and its antagonists in the treatment of cancer
Bagnato, A., Loizidou, M., Pflug, B., Curwen, J., & Growcott, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01217.x · Cited by 107
Tetrahydrobiopterin biosynthesis as an off-target of sulfa drugs
Haruki, H., Pedersen, M. G., Gorska, K. I., Pojer, F., & Johnsson, K. (2013) · Science · doi:10.1126/science.1232972 · Cited by 101
Kenna, J. G., Stahl, S. H., Eakins, J. A., Foster, A. J., Andersson, L. C., Bergare, J., Billger, M., Elebring, M., Elmore, C. S., & Thompson, R. A. (2015) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.220491 · Cited by 48
“Bosentan (Ro 47-0203; 4-tert-butyl-N-[6-(2hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2,29-bipyrimidin-4-yl]benzenesulfonamide) (Clozel et al., 1994) was synthesized by Medicinal Chemistry, AstraZeneca (Mölndal, Sweden).”
Method
Metadata
- Authors
- Clozel, M., Breu, V, Gray, G. A., Kalina, B., Löffler, B. M., Burri, K., Cassal, J. M., Hirth, G., Müller, M., & Neidhart, W.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 1994-07
- Volume
- 270
- Issue
- 1
- Pages
- 228-235
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W1910386836
- Cited by
- 661
- References
- 0
- FWCI
- 35.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.